Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder

Rebecca L Haffajee, Lewei Allison Lin, Amy S B Bohnert, Jason E Goldstick, Rebecca L Haffajee, Lewei Allison Lin, Amy S B Bohnert, Jason E Goldstick

Abstract

Importance: Opioid overdose deaths in the United States continue to increase, reflecting a growing need to treat those with opioid use disorder (OUD). Little is known about counties with high rates of opioid overdose mortality but low availability of OUD treatment.

Objective: To identify characteristics of US counties with persistently high rates of opioid overdose mortality and low capacity to deliver OUD medications.

Design, setting, and participants: In this cross-sectional study of data from 3142 US counties from January 1, 2015, to December 31, 2017, rates of opioid overdose mortality were compared with availability in 2017 of OUD medication providers (24 851 buprenorphine-waivered clinicians [physicians, nurse practitioners, and physician assistants], 1517 opioid treatment programs [providing methadone], and 5222 health care professionals who could prescribe extended-release naltrexone). Statistical analysis was performed from April 20, 2018, to May 8, 2019.

Exposures: Demographic, workforce, lack of insurance, road density, urbanicity, opioid prescribing, and regional division county-level characteristics.

Main outcome and measures: The outcome variable, "opioid high-risk county," was a binary indicator of a high (above national) rate of opioid overdose mortality with a low (below national) rate of provider availability to deliver OUD medication. Spatial logistic regression models were used to determine associations with being an opioid high-risk county.

Results: Of 3142 counties, 751 (23.9%) had high rates of opioid overdose mortality. A total of 1457 counties (46.4%), and 946 of 1328 rural counties (71.2%), lacked a publicly available OUD medication provider in 2017. In adjusted models, compared with the West North Central division, counties in the East North Central, Mountain, and South Atlantic divisions had increased odds of being opioid high-risk counties (East North Central: odds ratio [OR], 2.21; 95% CI, 1.19-4.12; Mountain: OR, 4.15; 95% CI, 1.34-12.89; and South Atlantic: OR, 2.99; 95% CI, 1.26-7.11). A 1% increase in unemployment was associated with increased odds (OR, 1.09; 95% CI, 1.03-1.15) of a county being an opioid high-risk county. Counties with an additional 10 primary care clinicians per 100 000 population had a reduced risk of being opioid high-risk counties (OR, 0.89; 95% CI, 0.85-0.93), as did counties that were micropolitan (vs metropolitan) (OR, 0.67; 95% CI, 0.50-0.90) and those that had an additional 1% of the population younger than 25 years (OR, 0.95; 95% CI, 0.92-0.98).

Conclusions and relevance: Counties with low availability of OUD medication providers and high rates of opioid overdose mortality were less likely to be micropolitan and have lower primary care clinician density, but were more likely to be in the East North Central, South Atlantic, or Mountain division and have higher rates of unemployment. Strategies to increase medication treatment must account for these factors.

Figures

Figure 1.. Opioid Overdose Death Rate per…
Figure 1.. Opioid Overdose Death Rate per 100 000 People by US County, 2015-2017
Opioid-overdose deaths were classified using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), based on the ICD-10 underlying cause-of-death codes X40 toX 45 (unintentional), X60 to X65 (suicide), or Y10 to Y15 (undetermined intent). Among the deaths with drug overdose as the underlying cause, opioid overdose deaths were identified using the following ICD-10 multiple cause-of-death codes: opium (T40.0), heroin (T40.1), natural and semisynthetic opioids (T40.2), methadone (T40.3), synthetic opioids excluding methadone (T40.4), or other and unspecific narcotics (T40.6).
Figure 2.. US Counties Lacking Any Publicly…
Figure 2.. US Counties Lacking Any Publicly Available Medication for Opioid Use Disorder (MOUD) Provider, 2017
Medication for opioid use disorder providers are defined to include publicly listed opioid treatment programs, buprenorphine-waivered clinicians, and/or extended-release naltrexone–prescribing clinicians in late 2017.
Figure 3.. Opioid High-Risk Counties With Low…
Figure 3.. Opioid High-Risk Counties With Low Rates of Medication for Opioid Use Disorder (MOUD) Treatment Providers and High Rates of Opioid Overdose Death
Low and high rates of MOUD providers defined as those below and greater than the national rate, respectively, in availability of 3 types of MOUD providers (publicly listed opioid treatment programs, buprenorphine-waivered clinicians, and extended-release naltrexone prescribers) in late 2017. Low and high rates of opioid overdose deaths defined as below and above the national rate of opioid overdose deaths, respectively, from 2015 to 2017.

References

    1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):-. doi:10.15585/mmwr.mm675152e1
    1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 5th ed Washington, DC: American Psychiatric Association; 2013.
    1. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication–assisted treatment. Am J Public Health. 2015;105(8):e55-e63. doi:10.2105/AJPH.2015.302664
    1. Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Behavioral Health Statistics and Quality Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. . Accessed May 8, 2019.
    1. Charumilind S, Latkovic T, Lewis R, Mendez-Escobar E; Healthcare Systems and Services Practice; McKinsey & Company. Why we need bolder action to combat the opioid epidemic. . Published September 2018. Accessed May 8, 2019.
    1. Lembke A, Chen JH. Use of opioid agonist therapy for Medicare patients in 2013. JAMA Psychiatry. 2016;73(9):990-992. doi:10.1001/jamapsychiatry.2016.1390
    1. Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013. JAMA. 2015;314(14):1515-1517. doi:10.1001/jama.2015.10345
    1. Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6S3):S230-S242. doi:10.1016/j.amepre.2017.12.022
    1. Chen Q, Larochelle MR, Weaver DT, et al. . Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019;2(2):e187621. doi:10.1001/jamanetworkopen.2018.7621
    1. Samet JH, Botticelli M, Bharel M. Methadone in primary care—one small step for Congress, one giant leap for addiction treatment. N Engl J Med. 2018;379(1):7-8. doi:10.1056/NEJMp1803982
    1. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321-329. doi:10.1016/j.jsat.2005.02.007
    1. Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967-968. doi:10.1001/jama.2017.0001
    1. Jarvis BP, Holtyn AF, Subramaniam S, et al. . Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188-1209. doi:10.1111/add.14180
    1. Comer SD, Sullivan MA, Yu E, et al. . Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218. doi:10.1001/archpsyc.63.2.210
    1. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;16(2):CD001333. doi:10.1002/14651858.CD001333.pub3
    1. Sordo L, Barrio G, Bravo MJ, et al. . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2(2):CD002207. doi:10.1002/14651858.CD002207.pub4.Copyright
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;8(3):CD002209. doi:10.1002/14651858.CD002209.pub2
    1. Degenhardt L, Larney S, Kimber J, et al. . The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306-1317. doi:10.1111/add.12536
    1. Schwartz RP, Gryczynski J, O’Grady KE, et al. . Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103(5):917-922. doi:10.2105/AJPH.2012.301049
    1. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974-1981. doi:10.1001/jamainternmed.2014.5416
    1. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22-35. doi:10.1080/10550887.2016.1100960
    1. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;9(5):CD011117. doi:10.1002/14651858.CD011117.pub2
    1. Larochelle MR, Bernson D, Land T, et al. . Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. doi:10.7326/M17-3107
    1. President’s Commission on Combatting Drug Addiction and the Opioid Crisis Final report of the President’s commission on combatting drug addiction and the opioid crisis. . Accessed May 8, 2019.
    1. Jones A, Honermann B, Sharp A, Millett G. Where multiple forms of medication-assisted treatment are available. Health Affairs Blog. doi:10.1377/HBLOG20180104.835958
    1. 8.12 Federal Opioid Treatment Standards. 2001:65-69. . Accessed May 8, 2019.
    1. Substance Abuse and Mental Health Services Administration Opioid treatment program directory. . Published 2017. Accessed September 19, 2017.
    1. Knudsen HK. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis. J Stud Alcohol Drugs. 2015;76(4):644-654. doi:10.15288/jsad.2015.76.644
    1. Stein BD, Pacula RL, Gordon AJ, et al. . Where is buprenorphine dispensed to treat opioid use disorders? the role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties. Milbank Q. 2015;93(3):561-583. doi:10.1111/1468-0009.12137
    1. 106th US Congress. Drug Addiction Treatment Act of 2000; 2000:2205-2206. . Accessed May 8, 2019.
    1. 114th US Congress. Comprehensive Addiction and Recovery Act of 2016. . Accessed May 8, 2019.
    1. Rinaldo SG, Rinaldo DW; American Society of Addiction Medicine. Advancing access to addiction medications: implications for opioid addiction treatment. . Published 2013. Accessed May 8, 2019.
    1. Knudsen HK, Havens JR, Lofwall MR, Studts JL, Walsh SL. Buprenorphine physician supply: relationship with state-level prescription opioid mortality. Drug Alcohol Depend. 2017;173(suppl 1):S55-S64. doi:10.1016/j.drugalcdep.2016.08.642
    1. Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-26. doi:10.1370/afm.1735
    1. Stein BD, Gordon AJ, Dick AW, et al. . Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104-111. doi:10.1016/j.jsat.2014.07.010
    1. Dick AW, Pacula RL, Gordon AJ, et al. . Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff (Millwood). 2015;34(6):1028-1034. doi:10.1377/hlthaff.2014.1205
    1. Andrilla CHA, Coulthard C, Patterson DG. Prescribing practices of rural physicians waivered to prescribe buprenorphine. Am J Prev Med. 2018;54(6S3):S208-S214. doi:10.1016/j.amepre.2018.02.006
    1. Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108-112. doi:10.1111/jrh.12307
    1. Abraham AJ, Andrews CM, Yingling ME, Shannon J. Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res. 2018;53(1):389-404. doi:10.1111/1475-6773.12686
    1. Jones CW, Christman Z, Smith CM, et al. . Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat. 2018;93:19-25. doi:10.1016/j.jsat.2018.07.008
    1. Langabeer JR, Gourishankar A, Chambers KA, Giri S, Madu R, Champagne-Langabeer T. Disparities between US opioid overdose deaths and treatment capacity: a geospatial and descriptive analysis. J Addict Med. 2019;00(00):1-7. doi:10.1097/ADM.0000000000000523
    1. University of Michigan Office of Research Ethics & Compliance Operations manual: part 4. . Published 2019. Accessed April 26, 2019.
    1. Equator Network The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. . Published 2019. Accessed April 25, 2019.
    1. Substance Abuse and Mental Health Services Administration Buprenorphine treatment practitioner locator. . Published 2017. Accessed September 19, 2017.
    1. Alkermes Inc Vivitrol: find a treatment provider. . Published 2017. Accessed May 23, 2019.
    1. US Census Bureau Census regions and divisions of the United States. . Accessed May 8, 2019.
    1. Centers for Disease Control and Prevention Multiple cause of death data. . Published 2018. Accessed January 9, 2018.
    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378-1382. doi:10.15585/mmwr.mm6450a3
    1. US Census Bureau American Community Survey (ACS). . Published 2017. Accessed May 8, 2019.
    1. Robert Wood Johnson Foundation County health rankings and roadmaps: rankings data & documentation. . Published 2017. Accessed May 1, 2018.
    1. US Census Bureau 2008-2017 Small area health insurance estimates (SAHIE) using the American Community Survey (ACS). . Published 2016. Accessed May 1, 2018.
    1. US Geological Survey National Geospatial Program The national map. . Published 2008. Accessed May 8, 2019.
    1. Centers for Disease Control and Prevention National Center for Health Statistics NCHS urban-rural classification scheme for counties. . Published 2017. Accessed May 1, 2018.
    1. Centers for Disease Control and Prevention U.S. county prescribing rates, 2016. . Published 2019. Accessed April 4, 2019.
    1. Harvard Dataverse MIT Election Data and Science Lab: county presidential election returns 2000-2016. Version 1. . Accessed April 4, 2019. doi:10.7910/DVN/VOQCHQ.
    1. US Census Bureau Geography: divisions. . Accessed May 8, 2019.
    1. Komaromy M, Duhigg D, Metcalf A, et al. . Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20-24. doi:10.1080/08897077.2015.1129388
    1. Wakeman SE, Barnett ML. Primary care and the opioid-overdose crisis—buprenorphine myths and realities. N Engl J Med. 2018;379(1):1-4. doi:10.1056/NEJMp1802741
    1. Yang YT, Weintraub E, Haffajee RL. Telemedicine’s role in addressing the opioid epidemic. Mayo Clin Proc. 2018;93(9):1177-1180. doi:10.1016/j.mayocp.2018.07.001
    1. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? a systematic review. PLoS One. 2017;12(10):e0186315. doi:10.1371/journal.pone.0186315
    1. Massachusetts Department of Public Health Opioid-related overdose deaths continue to decline in Massachusetts. . Published 2018. Accessed May 8, 2019.
    1. Case A, Deaton A. Mortality and morbidity in the 21st century. Brookings Pap Econ Act. 2017;2017:397-476. doi:10.1353/eca.2017.0005
    1. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182-186. doi:10.2105/AJPH.2017.304187
    1. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211-1212. doi:10.1001/jama.2016.10542
    1. Sigmon SC. The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. 2015;72(4):395-396. doi:10.1001/jamapsychiatry.2014.2421
    1. Lowder EM, Ray BR, Huynh P, Ballew A, Watson DP. Identifying unreported opioid deaths through toxicology data and vital records linkage: case study in Marion County, Indiana, 2011-2016. Am J Public Health. 2018;108(12):1682-1687. doi:10.2105/AJPH.2018.304683
    1. Ruhm CJ. Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999-2015. Addiction. 2018;113(7):1339-1344. doi:10.1111/add.14144
    1. Warner M, Hedegaard H. Identifying opioid overdose deaths using vital statistics data. Am J Public Health. 2018;108(12):1587-1589. doi:10.2105/AJPH.2018.304781
    1. Monnat SM. Factors associated with county-level differences in US drug-related mortality rates. Am J Prev Med. 2018;54(5):611-619. doi:10.1016/j.amepre.2018.01.040
    1. Ruhm CJ. Geographic variation in opioid and heroin involved drug poisoning mortality rates. Am J Prev Med. 2017;53(6):745-753. doi:10.1016/j.amepre.2017.06.009
    1. 115th Congress. H.R. 6: SUPPORT for Patients and Communities Act; 2018:668. . Accessed May 8, 2019.
    1. US Department of Health and Human Services HHS FY 2018 budget in brief—SAMHSA. . Published 2018. Accessed May 8, 2019.

Source: PubMed

3
Subscribe